Scholarlink

Background <p>We report a case of a 69-year-old patient negative for serum M-protein who was diagnosed with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) via renal biopsy.</p> Case presentation <p>A 69-year-old male presented with hematuria, edema, and rapidly progressive renal failure. Serum M-protein was negative, but renal biopsy confirmed IgG3-κ PGNMID with intense C3 deposition and an MPGN-like pattern. Rituximab was initiated, but due to a pulmonary infection, only one of the planned rituximab doses was administered. After infection resolution, the patient’s renal function gradually improved (serum creatinine from 914 to 134 µmol/L) under long-term corticosteroid maintenance. Whether this improvement resulted from the single rituximab dose, prolonged corticosteroids, resolution of sepsis-associated AKI, or natural disease course remains uncertain. This case underscores that PGNMID, though rare, should be considered in seronegative patients with unexplained glomerulonephritis, and highlights the critical role of renal biopsy.</p> Conclusions <p>PGNMID should be considered in rapidly progressive glomerulonephritis, even when M-protein is negative. In this patient, a single reduced dose of rituximab combined with prolonged corticosteroids was associated with a favorable renal outcome, suggesting that a B-cell–directed, clone-directed approach may be a reasonable option worth further evaluation in seronegative PGNMID. Nonetheless, causality cannot be established from a single case, and the relative contributions of the individual therapies remain uncertain. Further studies are needed to define the optimal treatment for this rare entity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rituximab and corticosteroids for M-protein-negative PGNMID: case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月24日

查看全文
  • Zhuolin Huang,
  • Shuopeng Yang,
  • Jun Cai,
  • Fengying Tang

摘要

Background

We report a case of a 69-year-old patient negative for serum M-protein who was diagnosed with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) via renal biopsy.

Case presentation

A 69-year-old male presented with hematuria, edema, and rapidly progressive renal failure. Serum M-protein was negative, but renal biopsy confirmed IgG3-κ PGNMID with intense C3 deposition and an MPGN-like pattern. Rituximab was initiated, but due to a pulmonary infection, only one of the planned rituximab doses was administered. After infection resolution, the patient’s renal function gradually improved (serum creatinine from 914 to 134 µmol/L) under long-term corticosteroid maintenance. Whether this improvement resulted from the single rituximab dose, prolonged corticosteroids, resolution of sepsis-associated AKI, or natural disease course remains uncertain. This case underscores that PGNMID, though rare, should be considered in seronegative patients with unexplained glomerulonephritis, and highlights the critical role of renal biopsy.

Conclusions

PGNMID should be considered in rapidly progressive glomerulonephritis, even when M-protein is negative. In this patient, a single reduced dose of rituximab combined with prolonged corticosteroids was associated with a favorable renal outcome, suggesting that a B-cell–directed, clone-directed approach may be a reasonable option worth further evaluation in seronegative PGNMID. Nonetheless, causality cannot be established from a single case, and the relative contributions of the individual therapies remain uncertain. Further studies are needed to define the optimal treatment for this rare entity.